GREENWICH LIFESCIENCES, INC. Shareholders' Equity
GREENWICH LIFESCIENCES, INC. (GLSI) had Shareholders' Equity of $3.12 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $3.12M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $5.27M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $353.22K.
- 2025-09-30: Stockholders' Equity Attributable to Parent $2.18M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $3.12M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $5.27M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $353.22K 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $604.30K 10-Q · filed 2026-08-11 | $1.44M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $200.48K 10-Q · filed 2026-08-11 | $1.31M 10-Q · filed 2025-05-20 |
| 2024-12-31 | $908.63K 10-Q · filed 2026-08-11 | $2.53M 10-K · filed 2025-04-15 |
| 2024-09-30 | $4.98M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $5.88M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $5.12M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $6.70M 10-K · filed 2026-06-01 | |
| 2023-09-30 | $8.85M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $10.65M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $11.68M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $13.21M 10-K · filed 2025-04-15 | |
| 2022-09-30 | $15.41M 10-Q · filed 2023-10-19 | |
| 2022-06-30 | $16.97M 10-Q · filed 2023-10-19 | |
| 2022-03-31 | $19.51M 10-Q · filed 2023-10-19 | |
| 2021-12-31 | $26.83M 10-K · filed 2024-04-15 | |
| 2021-09-30 | $28.46M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $29.16M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $29.75M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $27.63M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $4.66M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$1.46M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | -$1.42M 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$1.35M 10-K · filed 2022-03-21 | |
| 2019-09-30 | -$1.21M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | -$12.87M 10-Q · filed 2020-11-16 | |
| 2019-03-31 | -$10.27M 10-Q · filed 2020-11-16 | |
| 2018-12-31 | -$10.12M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |